Highlighting Deuruxolitinib for Alopecia Areata

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Common Comorbidities Associated With Alopecia Areata

EP: 3.Epidemiology Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

Now Viewing

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

EP: 20.Future Treatment of Patients With Alopecia Areata

EP: 21.Final Takeaways From the Panelists

Video content above is prompted by the following:

1. Mostaghimi: Deuruxolitinib has been evaluated in the THRIVE-AA1 and THRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?
   1. Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
   2. How does the durability of the different JAK inhibitors compare?